Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

42,492 --------------------- 100,504 51,410 --------------------- --------------------- BioMS Medical Corp. (A Development Stage Corporation) Consolidated Statements of Operations and Comprehensive Loss ------------------------------------------------------------------------- (expressed in thousands of Canadian dollars and shares, except per share amounts) Cumulative from inception to Years December 31, ended December 31, ------------ ------------------- 2008 2008 2007 $ $ $ Research and development Revenue earned from collaboration partner 52,561 52,561 - Research and development expenses (152,085) (46,502) (38,907) ------------ ------------------- (99,524) 6,059 (38,907) General and administrative expenses (42,605) (13,790) (7,490) Amortization of licensing costs (11,755) (1,472) (1,472) Amortization of property and equipment (517) (125) (134) ------------ ------------------- Loss from operations (154,401) (9,328) (48,003) Other income (expense) Investment income 8,779 2,436 1,644 Foreign exchange gain (loss)
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Steep Hill, the industry leader in ... intends to open a full service medical cannabis quality ... , bringing advanced scientific tools and methodology to the ... Hill is currently the only laboratory licensed by the ... contaminant testing in order to meet the recently adopted ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading ... Kate Black as Privacy Officer and Corporate Counsel. ... state privacy laws as well as health care regulations. ... she will be responsible for reviewing, updating and enhancing ... the U.S. and abroad. She joined the company January ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... safety and efficacy of Albuferon administered every four weeks in ... hepatitis C - , , ROCKVILLE, Md., June 19 ... today announced that Novartis has completed enrollment and initial dosing ... and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination ...
... Has Tentative FDA Approval and Expects Final Approval Shortly -- ... Inc. (NYSE: HSP ), the world leader in ... for the District of New Jersey has granted summary judgment ... chemotherapy medication Eloxatin(R), and that Hospira has tentative approval from ...
... WalkMS Participants - , , NEW YORK, June ... family, and other people living with multiple sclerosis, Saatchi & ... component of the "I Walk Because" program. The site ... social media applications. , , The site, ...
Cached Biology Technology:Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 2Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 3Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 4Hospira Receives Favorable Court Decision on Eloxatin(R) 2Hospira Receives Favorable Court Decision on Eloxatin(R) 3I Walk Because Program Gives Consumers a Voice 2I Walk Because Program Gives Consumers a Voice 3
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... IOF and ESCEO will be staging the ... largest bone meeting in Europe, to be held ... the pre-registration deadline of March 7, 2011 fast ... registration to the 1st IOF-ESCEO Pre-Clinical Symposium (from ...
... Scientists have published results that will forever change the ... replication and the prevention of DNA damage. ... to many problems including cancers. Researchers, funded by the ... Wellcome Trust and working at The University of Nottingham, ...
... Chase, MDA recent study accepted for publication in ... for the first time that maternal fructose intake during ... endocrinology. Fructose is a simple sugar found naturally ... dietary fructose, particularly due to calorically sweetened beverages, are ...
Cached Biology News:8 special sessions at European Congress on Osteoporosis and Osteoarthritis in Valencia 2Collisions of protein machines cause DNA replication derailment 2Maternal fructose intake impacts female and male fetuses differently 2
... Nuclease is a genetically engineered endonuclease. This ... and RNA while having no proteolytic activity. ... of conditions and possesses an exceptionally high ... acids from recombinant proteins, its use enables ...
...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known fish microRNAs ...
...
Biology Products: